173 related articles for article (PubMed ID: 26216437)
1. Anti-Hormonal Therapies for Premenopausal Patients--What did we Learn from the TEXT/SOFT Trials?
Valsecchi ME; Recondo G; de la Vega M; Greco M; Recondo G; Díaz Cantón E
Rev Recent Clin Trials; 2015; 10(2):90-100. PubMed ID: 26216437
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant treatment of premenopausal women with endocrine-responsive early breast cancer: design of the TEXT and SOFT trials.
Regan MM; Pagani O; Fleming GF; Walley BA; Price KN; Rabaglio M; Maibach R; Ruepp B; Coates AS; Goldhirsch A; Colleoni M; Gelber RD; Francis PA; ;
Breast; 2013 Dec; 22(6):1094-100. PubMed ID: 24095609
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Pagani O; Regan MM; Walley BA; Fleming GF; Colleoni M; Láng I; Gomez HL; Tondini C; Burstein HJ; Perez EA; Ciruelos E; Stearns V; Bonnefoi HR; Martino S; Geyer CE; Pinotti G; Puglisi F; Crivellari D; Ruhstaller T; Winer EP; Rabaglio-Poretti M; Maibach R; Ruepp B; Giobbie-Hurder A; Price KN; Bernhard J; Luo W; Ribi K; Viale G; Coates AS; Gelber RD; Goldhirsch A; Francis PA; ;
N Engl J Med; 2014 Jul; 371(2):107-18. PubMed ID: 24881463
[TBL] [Abstract][Full Text] [Related]
4. [Factors related to adjuvant ovarian function suppression in premenopausal breast cancer patients].
Liang Y; Chen XS; Wu JY; Huang O; Zong Y; Nie LJ; Fang Q; He JR; Zhu L; Chen WG; Li YF; Shen KW
Zhonghua Zhong Liu Za Zhi; 2016 May; 38(5):357-62. PubMed ID: 27188608
[TBL] [Abstract][Full Text] [Related]
5. The aromatase inhibitors (plus ovarian function suppression) in premenopausal breast cancer patients: ready for prime time?
Montagna E; Cancello G; Colleoni M
Cancer Treat Rev; 2013 Dec; 39(8):886-90. PubMed ID: 23725877
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant endocrine therapy for premenopausal women with hormone-responsive breast cancer.
Mathew A; Davidson NE
Breast; 2015 Nov; 24 Suppl 2():S120-5. PubMed ID: 26255743
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial.
Perrone F; De Laurentiis M; De Placido S; Orditura M; Cinieri S; Riccardi F; Ribecco AS; Putzu C; Del Mastro L; Rossi E; Tinessa V; Mosconi AM; Nuzzo F; Di Rella F; Gravina A; Iodice G; Landi G; Pacilio C; Forestieri V; Lauria R; Fabbri A; Ibrahim T; De Maio E; Barni S; Gori S; Simeon V; Arenare L; Daniele G; Piccirillo MC; Normanno N; de Matteis A; Gallo C
Eur J Cancer; 2019 Sep; 118():178-186. PubMed ID: 31164265
[TBL] [Abstract][Full Text] [Related]
8. Are SOFT and TEXT results practice changing and how?
Pagani O; Regan MM; Francis PA
Breast; 2016 Jun; 27():122-5. PubMed ID: 27107153
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant endocrine therapy for premenopausal women: risk stratification, type and duration.
Francis PA
Breast; 2019 Nov; 48 Suppl 1():S85-S88. PubMed ID: 31839169
[TBL] [Abstract][Full Text] [Related]
10. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients.
Abbas W; Rao RR
Indian J Cancer; 2019; 56(4):293-296. PubMed ID: 31607695
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibitor plus ovarian suppression as adjuvant therapy in premenopausal women with breast cancer.
Figg WD; Cook K; Clarke R
Cancer Biol Ther; 2014; 15(12):1586-7. PubMed ID: 25535893
[TBL] [Abstract][Full Text] [Related]
12. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
13. Luteininzing hormone releasing hormones analogs in combination with tamoxifen for the adjuvant treatment of premenopausal women with hormone receptor positive breast cancer.
Conte B; Poggio F; Del Mastro L
Expert Opin Pharmacother; 2017 Sep; 18(13):1357-1362. PubMed ID: 28764603
[TBL] [Abstract][Full Text] [Related]
14. Ovarian suppression in combination endocrine adjuvant therapy in premenopausal women with early breast cancer.
Chlebowski RT; Pan K; Col NF
Breast Cancer Res Treat; 2017 Jan; 161(2):185-190. PubMed ID: 27785653
[TBL] [Abstract][Full Text] [Related]
15. An Italian Delphi study to evaluate consensus on adjuvant endocrine therapy in premenopausal patients with breast cancer: the ERA project.
Pelizzari G; Arpino G; Biganzoli L; Cinieri S; De Laurentiis M; Del Mastro L; Di Leo A; Gori S; Guarneri V; Marchetti P; Puglisi F
BMC Cancer; 2018 Sep; 18(1):932. PubMed ID: 30261866
[TBL] [Abstract][Full Text] [Related]
16. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
17. Optimizing endocrine therapy for premenopausal and postmenopausal women with breast cancer.
Cianfrocca M; Wolff AC
Oncology (Williston Park); 2007 Jan; 21(1):63-9; discussion 69, 72, 75 passim. PubMed ID: 17313157
[TBL] [Abstract][Full Text] [Related]
18. The emerging role of aromatase inhibitors in the adjuvant management of breast cancer.
Nabholtz JM; Gligorov J
Rev Recent Clin Trials; 2006 Sep; 1(3):237-49. PubMed ID: 18473976
[TBL] [Abstract][Full Text] [Related]
19. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women.
Sharma R; Hamilton A; Beith J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004562. PubMed ID: 18843661
[TBL] [Abstract][Full Text] [Related]
20. [Endocrine adjuvant treatment specific features for young breast cancer women].
Petit T
Bull Cancer; 2019 Dec; 106(12S1):S24-S27. PubMed ID: 32008734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
